WTR Small-Cap Spotlight

Send us a text

Kirk Huntsman, Chairman and CEO of Vivos Therapeutics joins us on this week’s WTR Small-Cap Spotlight following the company announcement of its first known FDA clearance for a medical device in pediatric obstructive sleep apnea. He discusses what the FDA approval means for the millions of US children with this serious health condition. Kirk talks about how the pediatric market fits into Vivos’ new marketing and distribution strategy, as well as the progress with medical-based affiliations.

Send us a text

Patrick Gruber, Chief Executive Officer and Director at Gevo, Inc, joins Shawn Severson, Water Tower Research CEO, Co-founder and Head of Sustainability Research, and Peter Gastreich, analyst on WTR’s Natural Resources and Energy Transition sector teams. Gevo produces renewable fuels and develops related technologies that help customers meet carbon abatement goals as cost effectively as possible. Mr. Gruber discusses: 1) Gevo’s entry into low carbon ethanol and CCS with the $210 million Red Trail Acquisition in North Dakota; 2) multiple synergies of Red Trail with Gevo’s existing business lines; 3) Gevo’s move toward profitability and an improved financial condition; 4) how Gevo can value from CCS and durable 45Q tax credits; and other topics.

Send us a text

Tune in to the latest Small-Cap Spotlight FlashCast! Join WTR CEO & Co-Founder, Shawn Severson and Head of Consumer Products, Doug Lane as they discuss WTR's initiation of coverage on 1-800-FLOWERS.COM (FLWS).

Send us a text

Tune in to the latest Small-Cap Spotlight FlashCast! Join WTR CEO & Co-Founder Shawn Severson and Energy Transition and Sustainability Analyst Peter Gastreich as they discuss Gevo, Inc. Discover why Gevo is emerging as a cost leader in the fast growing sustainable aviation fuel (SAF) industry and how the company's new entry into low-carbon ethanol and carbon capture and sequestration (CCS) fit into management's strategy. 

Send us a text

In our latest episode of Small-Cap Spotlight, Tim Gerdeman, Vice Chair & Co-Founder and Chief Marketing Officer discusses the Unusual Machines (UMAC) and its growth potential with WTR technology analyst Dr. John Roy and UMAC CEO Dr. Allan Evans.

Unusual Machines, Inc. is a development stage technology company, which engages in the provision of drone solutions with a focus on first-person view (FPV) technology. It offers products to entertainment, recreation, and competitive racing industries. The company was founded on July 11, 2019, and is headquartered in Orlando, FL.

Send us a text

In this week's episode of WTR Small-Cap Spotlight, Tim Gerdeman, WTR's Vice-Chair, Co-Founder, and Chief Marketing Officer, hosts Patrick Quirk, Senior VP and General Manager of Opengear. They dive into Opengear's pivotal role in industrial IoT and network resilience, focusing on data center operations and cybersecurity. As well as, exploring how AI is revolutionizing data centers by enhancing efficiency and reducing power consumption. 

Send us a text

In this week's episode of WTR Small-Cap Spotlight, we dive into the world of digital security with Dr. Chris Pierson, Founder and CEO of BlackCloak, hosted by WTR's Dr. John Roy, Managing Director of Technology Research and Tim Gerdeman, Vice Chair & Co-Founder and Chief Marketing Officer. We explore how BlackCloak provides tailored cybersecurity and privacy protection solutions for high-profile individuals, safeguarding against cyber threats like identity theft and data breaches in both professional and personal spheres. 

Send us a text

In the debut episode of the newly rebranded “WTR Small-Cap Spotlight”, Water Tower Research Co-Founders Shawn Severson and Tim Gerdeman dive into the evolving dynamics of the U.S. small-cap investment landscape. They discuss myriad dynamics of the U.S. small-cap investment landscape, and the strategic importance of uncovering value in under-covered small-cap stocks. This episode sets the stage for a series dedicated to helping investors discover actionable insights and high-impact opportunities in the small-cap market.

Send us a text

Novel Psychedelics drug developer Cybin's CEO Doug Drydale joins WTR's Tim Gerdman and Robert Sassoon to talk about the company's fast-track development into a late-stage clinical development company, and what differentiates Cybin from other drug developers in the psychedelics space. Drysdale discusses Cybin's plans and priorities for its development pipeline going forward and talks about the company's extensive IP real estate. He also shares his perspectives on the regulatory uncertainty currently surrounding Lykos's MDMA-AT and how Cybin is dealing with it to its benefit 

Send us a text

Jack Lu, Director of Corporate Development, of Ainos joins the Water Tower Hour Podcast to provide a business overview and discuss the proprietary AI Nose platform. He talks about the underlying technologies of AI Nose and the advantages of lead product Ainos Flora over traditional STI tests. We get a sense of how Ainos Flora could disrupt the STI test market and the other opportunities for AI Nose beyond healthcare.